Saturday, October 3, 2026

Coffee Futures Is 5% Up In The Last 10 Sessions

Coffee Futures Is 5% Up In The Last 10 Sessions

(VIANEWS) - Coffee (KC) has been up by 5.45% for the last 10 sessions. At 04:50 EST on Friday, 8 March, Coffee (KC) is $189.70.

Volume

Today's last reported volume for Coffee is 943, 95.38% below its average volume of 20425.79.

Volatility

Coffee's last week, last month's, and last quarter's current intraday variation average was 0.14%, 0.23%, and 2.95%, respectively.

Coffee's highest amplitude of average volatility was 2.18% (last week), 1.89% (last month), and 2.95% (last quarter), respectively.

News about

  • According to FXStreet on Wednesday, 6 March, "The US API Weekly Crude Oil Stock data reported build-in stockpiles of 0.423 million barrels for the week ending on March 1, contrary to market expectations of a decrease to 2.6 million barrels from the previous 8.428 million barrels. ", "Traders will now turn their attention to the US EIA Crude Oil Stocks Change report, scheduled for release on Wednesday, with market expectations leaning towards a reduction in the number of barrels in stock of crude oil and its derivatives."
  • WTI hovers around $78.50 after recent gains on US crude oil stocks change. According to FXStreet on Thursday, 7 March, "US Energy Information Administration (EIA) showed that Crude Oil Stocks Change rose for a sixth week in a row, building by 1.367 million barrels against the expected 2.116 million barrels and 4.199 million barrels prior. ", "Additionally, US API Weekly Crude Oil Stock data reported build-in stockpiles of 0.423 million barrels, contrary to market expectations of a decrease to 2.6 million barrels from the previous 8.428 million barrels."

More news about Coffee (KC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com